Get the Stockscreener App
4.92
0.81%
-0.010
Cingulate Inc stock is traded at $4.92, with a volume of 187.28K.
It is down -0.81% in the last 24 hours and up +7.00% over the past month.
Cingulate Inc is a clinical-stage biopharmaceutical company focused on the development of products utilizing its drug delivery platform technology that enables the formulation and manufacture of once-daily tablets of multi-dose therapies, with an initial focus on the treatment of Attention Deficit/Hyperactivity Disorder (ADHD) and anxiety. The Company is developing two proprietary, first-line stimulant medications, CTx-1301 (dexmethylphenidate) and CTx-1302 (dextroamphetamine), for the treatment of ADHD intended for all patient segments: children, adolescents, and adults. The company focuses on the treatment of Attention Deficit/Hyperactivity Disorder (ADHD) and anxiety, and identifying and evaluating additional therapeutic areas to use PTR technology to develop future product candidates.
See More
Previous Close:
$4.93
Open:
$4.92
24h Volume:
187.28K
Relative Volume:
0.29
Market Cap:
$65.46M
Revenue:
-
Net Income/Loss:
$-27.71M
P/E Ratio:
-1.1545
EPS:
-4.2615
Net Cash Flow:
$-19.77M
1W Performance:
+5.16%
1M Performance:
+7.00%
6M Performance:
+26.36%
1Y Performance:
+8.43%
1-Day Range:
$4.85
$5.13
1-Week Range:
$4.65
$5.17
52-Week Range:
$3.16
$11.89
Cingulate Inc Stock (CING) Company Profile
Name
Cingulate Inc
Sector
Industry
Phone
(913) 942-2300
Address
1901 W. 47TH PLACE, KANSAS CITY
Compare CING vs VRTX, REGN, ARGX, ALNY, RVMD
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
CING
Cingulate Inc
|
4.86 | 66.40M | 0 | -27.71M | -19.77M | -4.2615 |
VRTX
Vertex Pharmaceuticals Inc
|
448.25 | 114.33B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
611.59 | 64.47B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
872.29 | 54.99B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
279.31 | 38.42B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
157.49 | 34.03B | 742.00K | -1.37B | -1.07B | -7.0731 |
Cingulate Inc Stock (CING) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jan-10-25 | Initiated | ROTH MKM | Buy |
| Dec-22-23 | Downgrade | Laidlaw | Buy → Hold |
Cingulate Inc Stock (CING) Latest News
Why Is CING Stock Jumping Over 4% In Overnight Trading? - Stocktwits
CING Q1 2026 Earnings: Wider-than-expected loss as pre-revenue biotech continues pipeline development - newsline.com
Insider Makes Bold Move With Major Cingulate Inc. Stock Purchase - TipRanks
CING Maintained by Ascendiant Capital -- Price Target Lowered to $52 - GuruFocus
Cingulate director Hargroves buys $490,271 of common stock By Investing.com - Investing.com Australia
Cingulate director Hargroves buys $490,271 of common stock - Investing.com
Cingulate (CING) director-linked LLC buys shares, warrants as options granted - Stock Titan
Cingulate (CING) director reports initial share and warrant holdings - Stock Titan
Oncology Institute To Rally Over 64%? Here Are 10 Top Analyst Forecasts For Monday - Benzinga
Stonegate Capital Partners Updates Coverage on Cingulate Inc. (NASDAQ: CING) Following FDA Complete Response Letter - citybuzz -
FDA focuses on manufacturing for Cingulate CTx-1301, not safety - Stock Titan
FDA slaps CRL on Cingulate’s CTx-1301 NDA - The Pharma Letter
Stonegate Capital Partners Updates Coverage on Cingulate Inc. (CING) 1Q26 - TMX Newsfile
FDA Issues Complete Response Letter for Cingulate's Once-Daily ADHD Drug CTx-1301 - AJMC
FDA Issues Complete Response Letter for Cingulate ADHD Drug CTx-1301 - Patient Care Online
Biopharma bites: FDA rebuffs Cingulate's ADHD hopeful, plus Contraline's male contraceptive funding - FirstWord Pharma
FDA rejects Cingulate's application for ADHD medicine - The Business Journals
FDA Sends Complete Response Letter for Cingulate's CTx-1301 | PharmExec - PharmExec.com
FDA Issues CRL for CTx-1301 in ADHD Over CMC Concerns - HCPLive
Cingulate Gets FDA Request for Updates on ADHD Drug Application - Moomoo
Cingulate Inc - Reuters
Cingulate Inc. Q1 2026 Earnings: Wider-than-Expected Loss, Yet Shares Rally 19%Earnings Preview - thelegaladvocate.com
Cingulate Receives FDA Complete Response Letter for CTx-1301 ADHD Drug; No Clinical Safety or Efficacy Concerns Identified 1 - Minichart
FDA declines to approve Cingulate's ADHD treatment over manufacturing issues - Reuters
FDA Sends CRL to Cingulate for CTx-1301 - PharmExec.com
ADHD drug delivery specialist Cingulate hit with manufacturing-related FDA rejection - Fierce Pharma
Cingulate stock tumbles after FDA issues response letter - Investing.com
Cingulate receives FDA complete response letter for ADHD drug By Investing.com - Investing.com South Africa
Cingulate stock tumbles after FDA issues response letter By Investing.com - Investing.com Australia
Cingulate receives FDA complete response letter for ADHD drug - Investing.com
Cingulate Faces FDA Delay But Maintains ADHD Drug Plans - TipRanks
Cingulate Receives Complete Response Letter from FDA for CTx-1301 - The Manila Times
Cingulate receives FDA complete response letter for CTx-1301; CMC requests, ~$30M cash - TradingView
FDA sends CRL on Cingulate (NASDAQ: CING) ADHD drug CTx-1301 - Stock Titan
US FDA declines to approve Cingulate's ADHD drug - Yahoo Finance
Reportable, Inc. - TMX Newsfile
Cingulate’s ADHD Drug Is Near An FDA Verdict - Finimize
Cingulate Nears FDA Verdict on ADHD Drug Amid Manufacturing Hurdles - BriefGlance
Executive pay and equity plan on agenda at Cingulate (NASDAQ: CING) - Stock Titan
Cingulate Awaits FDA Decision On ADHD Therapy CTx-1301 - RTTNews
CING Q1 2026 Earnings: EPS Misses Estimates as Clinical-Stage Biotech Continues R&D InvestmentEarnings Cycle Outlook - The League of Women Voters of Texas
CING Q1 2026 Earnings: Wider-than-Expected Loss Sends Shares LowerRevenue Growth Outlook - thelegaladvocate.com
Cingulate Inc. (CING) Plunges 17% as Selling Pressure IntensifiesEase of Movement - thelegaladvocate.com
Analysts Are Bullish on These Healthcare Stocks: Roche Holding AG (RHHVF), Cingulate Inc (CING) - The Globe and Mail
H.C. Wainwright Maintains Cingulate(CING.US) With Buy Rating, Maintains Target Price $20 - Moomoo
Cingulate Inc. (CING) Surges 8.4% as Bullish Momentum BuildsImpulse Wave - thelegaladvocate.com
CING Reiterated by HC Wainwright & Co. -- Price Target Maintained at $20 - GuruFocus
Cingulate stock reaffirmed at Buy by H.C. Wainwright ahead of FDA decision - Investing.com UK
Cingulate Inc Stock (CING) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.61%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):